93967-77-2

Usage

Uses

Used in Pharmaceutical Industry:
(2S,4S)-1-tert-butyl 2-methyl 4-(methylthio)pyrrolidine-1,2-dicarboxylate is utilized as an intermediate in the synthesis of pharmaceutical compounds due to its unique structural features and chiral centers. Its specific configuration allows for targeted drug design and development, potentially leading to more effective and selective medications.
Used in Organic Synthesis:
In the field of organic synthesis, (2S,4S)-1-tert-butyl 2-methyl 4-(methylthio)pyrrolidine-1,2-dicarboxylate serves as a versatile building block for the creation of various organic molecules. Its multiple functional groups and chiral centers enable it to participate in a range of chemical reactions, facilitating the synthesis of complex organic compounds for research and industrial applications.

Upstream product

• 2584-71-6 cis-hydroxy-D-proline 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 84520-67-2 (2S,4R)-4-(methylsulfonyloxy)pyrrolidine-1,2-dicarboxylic acid 1-tert-butylester-2-methylester 
• 5188-07-8 sodium thiomethoxide 
• 1064036-63-0 (2R,4R)-4-Hydroxy-pyrrolidine-2-carbonyl chloride 
• 114676-47-0 (2R,4R)-4-Hydroxy-pyrrolidine-2-carboxylic acid methyl ester 
• 114676-69-6 (2R,4R)-1-tert-butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate 
• 77-78-1 dimethyl sulfate 
• 161458-02-2 methyl (2R,4S)-N-Boc-4-(acetylthio)prolinate 
• 148017-31-6 N-tert-Butoxycarbonyl-trans-4-formyloxy-D-proline methyl ester 
• 135042-17-0 (2R,4S)-1-tert-butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate 
• 161458-04-4 methyl (2R,4R)-N-Boc-4-(acetylthio)prolinate 

Downstream Products

• 188109-89-9 (2S,4S)-4-methylsulfanyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 
• 1373164-85-2 (2S,4S)-tert-butyl 2-(5-(4-bromophenyl)-1H-imidazol-2-yl)-4-(methylthio)pyrrolidine-1-carboxylate 

Relevant academic research and scientific papers

TRI-SUBSTITUTED HETEROARYL DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS

The present disclosure provides certain tri-substituted heteroaryl derivatives that are Src Homology-2 phosphatase (SHP2) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of SHP2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Compounds for inhibiting HCV (hepatitis C virus), pharmaceutical composition and application of compounds or pharmaceutical composition

The invention discloses compounds for inhibiting HCV (hepatitis C virus), pharmaceutical composition and an application of the compounds or the pharmaceutical composition. The compounds are compoundsshown in formula (I) or a stereoisomer, geometric isomer, a tautomer, an enantiomer, sulfur oxide, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compounds shown in formula (I); the compounds are effective antiviral drugs, especially can be used for inhibiting the function of NS5A protein encoded by the HCV, thereby effectively inhibiting the HCV.The method for preventing and/or treating drugs or diseases associated with the HCV by the compounds or the composition containing the new compounds has good market development prospects.

POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS

The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and othe

Ac-31>-CCK4 Analogs: Synthesis and Implications for the CCK-B Receptor-Bound Conformation

It has been reported that substitution of the Met31 residue in Boc-CCK4 (Boc-Trp30-Met31-Asp32-Phe33-NH2, CCK33 numbering) by trans-3-propyl-L-proline yields a highly potent and selective CCK-B agonist.To further explore the structural requirements of the Met31 side chain in the receptor-bound conformation of CCK4, we have synthesized several Ac-CCK4 analogs containing substitution of Met31 by 3- and 4-(alkylthio)-substituted proline derivatives.To this end we have developed novel synthetic routes to enantiomerically pure N-Boc-4-cis- and -trans-(methylthio)prolines and racemic N-Boc-3-cis- and -trans-prolines.The protected mercaptoprolines were incorporated into Ac-CCK4 analogs using SPPS and were alkylated using various electrophiles following cleavage from the solid support.Binding assays reveal that 3-(alkylthio)prolines analogs have higher affinities at the CCK-B receptor than the corresponding 4-(alkylthio)proline analogs, and that trans-3-(alkylthio)proline analogs had higher affinities than corresponding cis-3-(alkylthio)proline analogs.Within both the cis- and trans-3-(alkylthio)proline series, the order of potency was found to be Me 431>.Comparison of the low-energy structures calculated for several high-affinity Ac-CCK4 analogs reveal a common geometry which we propose to be the CCK-B receptor-bound conformation.This model shows grouping of the hydrophobic side chains of Trp, Met, and Phe at one side of the molecule and the hydrophilic side chain of Asp and the C-terminal carboxamide at the other side.